Haemonetics (HAE) Expected to Announce Earnings on Thursday

Haemonetics (NYSE:HAE – Get Free Report) is expected to issue its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.08 per share and revenue of $327.8930 million for the quarter. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Interested persons can check the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 EPS. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Get Haemonetics alerts:

Haemonetics Price Performance

Shares of NYSE HAE traded down $0.76 during trading hours on Tuesday, reaching $86.03. 97,237 shares of the stock traded hands, compared to its average volume of 842,022. The company has a market capitalization of $3.91 billion, a P/E ratio of 42.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.52. Haemonetics has a 52-week low of $47.31 and a 52-week high of $88.58. The company’s 50-day simple moving average is $75.53 and its two-hundred day simple moving average is $66.14. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53.

Analysts Set New Price Targets

Several research firms have weighed in on HAE. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, June 25th. Citigroup restated a “buy” rating on shares of Haemonetics in a report on Wednesday, July 29th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Barrington Research reduced their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.89.

Get Our Latest Stock Report on Haemonetics

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth $26,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 396 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Haemonetics in the 4th quarter worth $34,000. UMB Bank n.a. boosted its holdings in shares of Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 306 shares during the last quarter. Finally, Parallel Advisors LLC boosted its holdings in shares of Haemonetics by 172.9% during the 4th quarter. Parallel Advisors LLC now owns 625 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 396 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

(Get Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

Featured Stories

• Five stocks we like better than Haemonetics
• Dodging Deutsche Telekom: T-Mobile’s Strategic Win
• GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
• Tether Strikes Gold: Crypto’s Physical Pivot
• Jersey Mike’s Serves Fresh Gains After IPO Stumble

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.